Comparison of Robot-Assisted and Laparoscopic Partial Nephrectomy for Completely Endophytic Renal Tumors: A High-Volume Center Experience.

Journal: Journal of endourology
Published Date:

Abstract

To compare the perioperative, functional, and oncologic outcomes of robot-assisted partial nephrectomy (RAPN) and laparoscopic partial nephrectomy (LPN) for completely endophytic renal tumors (three points for the "E" element of the R.E.N.A.L. scoring system). We retrospectively reviewed patients who underwent either RAPN or LPN between 2013 and 2016. Baseline characteristics, perioperative, functional, and oncologic outcomes were compared. Univariable and multivariable logistic analyses were performed to determine factors associated with pentafecta achievement (ischemia time ≤25 minutes, negative margin, no perioperative complication, return of estimated glomerular filtration rate [eGFR] to >90% from baseline, and no chronic kidney disease upstaging). No significant differences between RAPN LPN were noted for operating time (105 minutes 108 minutes,  = 0.916), estimated blood loss (50 mL 50 mL,  = 0.130), renal artery clamping time (20 minutes 20 minutes,  = 0.695), rate of positive margins (3.3% 2.0%,  = 1.000), and postoperative complication rates (18.0% 21.6%,  = 0.639). RAPN was associated with a higher direct cost ($11240 $5053,  < 0.001). There were no significant differences in pathology variables, rate of eGFR decline for postoperative 12-month (9.8% 10.6%,  = 0.901) functional follow-up. Multivariate analysis identified that only RENAL score was independently associated with the pentafecta achievement. For completely endophytic renal tumors, both RAPN and LPN have excellent and similar results. Both operation techniques remain viable options in the management of these cases.

Authors

  • Liangyou Gu
    Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, PLA Medical School, Beijing, China.
  • Kan Liu
    Department of Urology, Hunan Cancer Hospital, Changsha, Hunan, China.
  • Donglai Shen
    Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, PLA Medical School, Beijing, China.
  • Hongzhao Li
    Department of Urology, Chinese People's Liberation Army General Hospital, Beijing, 100039 China.
  • Yu Gao
    Department of Radiology Center, The First Affiliated Hospital of Xinxiang Medical University, Xin Xiang, China.
  • Qingbo Huang
    Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, PLA Medical School, Beijing, China.
  • Yang Fan
    Colby College, Waterville, Maine, United States of America.
  • Qing Ai
    Department of Urology, Chinese People's Liberation Army General Hospital, Beijing, 100039 China.
  • Yongpeng Xie
    Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Yuanxin Yao
    Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China.
  • Songliang Du
    School of Medicine, Nankai University, Tianjin, China.
  • Xupeng Zhao
    Department of Urology, Chinese People's Liberation Army General Hospital, Beijing, 100039 China.
  • Baojun Wang
    Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China.
  • Xin Ma
    Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Xu Zhang
    China CDC Key Laboratory of Environment and Population Health, National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China.